Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide is indicated for hypertension management, targeting the renin‑angiotensin system and calcium‑channel pathways.

• Hypertension: provides combined blood pressure reduction through three complementary mechanisms.
• High‑risk cardiovascular patients: helps achieve target blood pressure when monotherapy is insufficient.
• Edema associated with hypertension therapy: mitigates fluid retention via the thiazide diuretic component.
• Stroke prevention (adjunct): contributes to lower stroke risk by maintaining optimal blood pressure levels.
• Chronic kidney disease with hypertension: assists in slowing renal function decline by controlling systemic pressure.

• The combination product works by three mechanisms: olmesartan medoxil blocks angiotensin II type 1 receptors, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide reduces sodium and water reabsorption in the distal convoluted tubule, decreasing plasma volume. Together these actions produce additive blood‑pressure‑lowering effects.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema
• Flushing
• Fatigue
• Cough

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Electrolyte disturbances (e.g., hyponatremia, hyperkalemia)
• Angio‑edema
• Liver function abnormalities
• Pancreatitis

When prescribing this combination, clinicians should consider several safety aspects.

• Renal function monitoring: assess creatinine and electrolytes before and during therapy.
• Hepatic impairment: use cautiously and adjust dose if needed.
• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity.
• Hyperkalemia risk: monitor serum potassium, especially when combined with potassium‑sparing agents.
• Orthostatic hypotension: advise patients to rise slowly from sitting or lying positions.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of renal dysfunction and hyperkalemia.
• Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): elevate amlodipine levels, raising hypotension risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Lithium: concurrent use can increase lithium concentrations, risking toxicity.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.